Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland

[1]  Colin Simpson,et al.  First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales , 2022, PLoS medicine.

[2]  M. Bertrand,et al.  Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older. , 2021, JAMA.

[3]  K. Khunti,et al.  Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study , 2021, BMJ.

[4]  P. McKeigue,et al.  Association of cerebral venous thrombosis with recent COVID-19 vaccination: case-crossover study using ascertainment through neuroimaging in Scotland , 2021, BMC Infectious Diseases.

[5]  S. de Lusignan,et al.  First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland , 2021, Nature Medicine.

[6]  C. Robertson,et al.  Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study , 2021, BMJ.

[7]  H. Sørensen,et al.  Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study , 2021, BMJ.

[8]  D. Goldblatt,et al.  Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination , 2021, The New England journal of medicine.

[9]  Fridtjof Lund-Johansen,et al.  Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination , 2021, The New England journal of medicine.

[10]  Andreas Greinacher,et al.  Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination , 2021, The New England journal of medicine.

[11]  G. Koh.  Faculty Opinions recommendation of Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[12]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[13]  Colin Simpson,et al.  COVID-19 in Pregnancy in Scotland (COPS): protocol for an observational study using linked Scottish national data , 2020, BMJ Open.

[14]  Colin Simpson,et al.  Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II): protocol for an observational study using linked Scottish national data , 2020, BMJ Open.

[15]  Colin Simpson,et al.  The UK hibernated pandemic influenza research portfolio: triggered for COVID-19 , 2020, The Lancet Infectious Diseases.

[16]  Colin Simpson,et al.  The UK's pandemic influenza research portfolio: a model for future research on emerging infections. , 2018, The Lancet. Infectious diseases.

[17]  Colin Simpson,et al.  Evaluating the effectiveness, impact and safety of live attenuated and seasonal inactivated influenza vaccination: protocol for the Seasonal Influenza Vaccination Effectiveness II (SIVE II) study , 2017, BMJ Open.

[18]  J. Wardle,et al.  Sleep and nighttime energy consumption in early childhood: a population‐based cohort study , 2015, Pediatric obesity.

[19]  M. Kolczak,et al.  Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations. , 2006, Journal of clinical epidemiology.

[20]  Ping Li,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020 .